Home Featured Page 134

Featured

Latest

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

International Conference on Assisted Dying and Other End of Life Care (ICEL5)

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University...

Braxia Scientific Announces Voting Results from the Annual General and Special...

PT369 – Chronic Pain and Phantom Limb Pain: Could Psilocybin Be...

Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics

Reunion Neuroscience to Present at Upcoming November Conferences

Numinus to Participate in Wonderland: Miami on November 3-5, 2022

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With...

Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch...

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

PT368 – Ketamine, Group Work, and the Power of Just Being...

1...133134135...303 Page 134 of 303

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural...

International Conference on Assisted Dying and Other End of Life Care...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural Event on Maui

International Conference on Assisted Dying and Other End of Life Care (ICEL5)

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University...

Braxia Scientific Announces Voting Results from the Annual General and Special...

PT369 – Chronic Pain and Phantom Limb Pain: Could Psilocybin Be...

Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics

Reunion Neuroscience to Present at Upcoming November Conferences

Numinus to Participate in Wonderland: Miami on November 3-5, 2022

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With...

Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch...

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

PT368 – Ketamine, Group Work, and the Power of Just Being...

EDITOR PICKS

Areyto Boriken – Ethnobotanical Adventure

The Ram Dass Institute of Psychedelic Studies with The Dying Inaugural...

International Conference on Assisted Dying and Other End of Life Care...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY